ArticleCancer immunology, immunotherapy : CII2023

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.

Fabrizio Nelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.